[Treatment of prostatic cancer].
D000230:Adenocarcinoma / Q000532:radiotherapy; D000368:Aged; D001918:Brachytherapy; D002588:Cesium Radioisotopes / Q000627:therapeutic use; D003534:Cyproterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004967:Estrogens / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007495:Iridium / Q000627:therapeutic use; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D017329:Triptorelin Pamoate
D002588:Cesium Radioisotopes; D004967:Estrogens; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D007495:Iridium; D017373:Cyproterone Acetate; D003534:Cyproterone
Traitement du cancer prostatique.